This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients.Methods:
A multicenter, single-arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8 weeks. The primary endpoint was ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8.Results:
A total of 316 patients were enrolled; 295 were included in the effectiveness analysis; 66.8% (197/295) achieved ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Nine patients discontinued treatment because of adverse events.Discussion:
Amisulpride had clinical effectiveness and was relatively well tolerated in Chinese patients with schizophrenia.